

# Effective Dendritic Cell-based Immunotherapeutic Vaccines for Acute Myeloid Leukemia (AML)

Maryam Nourizadeh<sup>1</sup>, Jamshid Hadjati<sup>2\*</sup>

<sup>1</sup> Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran.

<sup>2</sup> Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Accepted Mar 09, 2015

## ABSTRACT

Acute myeloid leukemia (AML) is a type of poor prognosis hematological malignancies characterized by heterogeneous clonal expansion of myeloid progenitors. Leukemic stem cells are thought to form the majority of a cell population in minimal residual diseases (MRDs) which are resistant to current chemotherapeutic regimens and mediate disease relapse. Current therapeutic vaccine strategies have developed to mount effective anti-leukemic immunity and eradicate the MRDs. Dendritic cells (DCs) are the most professional antigen-presenting cells to elicit efficient anti-leukemic immune responses. In this review article, we present the possibility of generating AML blast-targeted DCs, especially leukemia-derived DCs and their appropriate maturation protocols and particularly the synergistic effects of TLR agonists. We also discuss about the *in vitro* evaluation of the generated DCs, some reported outcomes of DC-based clinical trials as well as the possibility of combination therapy to improve the efficacy of DC-based vaccines in AML patients.

**KEYWORDS:** AML-DC, DC-based cancer vaccine, acute myeloid leukemia (AML)

## INTRODUCTION

Hematological malignancies are cancers that affect blood and different organs like bone marrow and lymph nodes. Considering the close relationship between the immune system cells, a disease disturbing one of the three compartments will often influence the others as well [1]. While unusual in solid tumors, chromosomal translocations are a common cause of liquid tumors. This feature leads to a different approach in diagnosis and treatment of hematological malignancies [2]. AML is a type of hematological malignancies characterized by heterogeneous clonal disorder of hematopoietic progenitor cells and the most common acute leukemia in adults, with a poor prognosis and an overall survival rate of only 23.6 % at 5 years [3, 4]. It is also known by an increase in the number of myeloid cells in the marrow and an arrest in their maturation, frequently resulting in hematopoietic insufficiency (*i.e.* granulocytopenia, thrombocytopenia, or anemia) with or without leukocytosis [5].

Recent studies have revealed that the heterogeneity of malignant cells relates to the previously defined immature

progenitors within the bulk of leukemic cells which are intrinsically resistant to chemotherapy and are able to repopulate the stem cells [6]. These newly-adopted "leukemia stem cells (LSCs)" share the most relevant features of the normal hematopoietic stem cells (HSCs) such as the self-renewal potential and dormant status. It would be difficult to find various pools of leukemic stem cells within the individual patients which differ both phenotypically and molecularly [7, 8].

Despite intensive consolidation chemotherapy in AML patients, the relapses occur in 50% of the patients due to the presence of minimal residual disease (MRD) [3, 9, 10]. Since leukemic stem cells are thought to consist the most of cell population in MRDs, their study also has potentially promising clinical implications. On the other hand, while achieving complete remission (CR) mainly depends on high-dose chemotherapy, the maintenance protocols as well as different strategies for the induction or restoration of the immune pressure against LSCs are needed for several months or years after intensive chemotherapies [3]. Based on the major role of the immune system in the prevention and control of leukemia, alternative therapeutic approaches other than intensive chemotherapy or hematopoietic stem cell transplantation (HSCT) have been explored to modulate the immune system [1, 11, 12].

**\*Corresponding Author:** Jamshid Hadjati, Ph.D; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, 2th floor, Building #7, Poursina Ave., 16 Azar St., Keshavarz Blvd., Tehran, Iran.

**Email:** : hajatij@sina.tums.ac.ir

**Tel/Fax:** (+98) 21 88577662

Regarding the prominent role of a tumor-specific T cell response in relapse prevention, there is a need to explore alternative treatments for notably maintaining the remission phase in AML patients. It would be a promising treatment approach to reverse the tumor-mediated immunosuppression as a consequence of different rationales such as a lack of adequate expression of costimulatory molecules, major histocompatibility complex (MHC) molecules, or tumor-associated antigens (TAAs) on cancer cells [13]. Recent studies or clinical trials have been focused on active cancer immunotherapy approaches like cell-based therapies. Dendritic cell (DC)-based vaccination with the ability to elicit cytotoxic T cell (CTL) responses that can eliminate residual tumor cells is therefore of great interest [14].

#### **DC vaccination: A cell-based cancer immunotherapy approach as an alternative medicine**

Cancer immunotherapy is a collection of methods using the immune system to fight against the cancers. This can be either through the immunization of the patient (e.g., by administering a cancer vaccine) in order to train the patient's own immune system for recognizing and destroying the tumor cells or through the administration of therapeutic antibodies as drugs, to recruit the patient's immune system for fighting the tumor cells [15-18]. Cell-based immunotherapy is another major entity of cancer immunotherapy. This involves immune cells such as the natural killer cells (NK cells), lymphokine activated killer cells (LAK cells), CTLs, DCs, etc. which are either activated in vivo by administering certain cytokines such as interleukins or are isolated, enriched and transfused to the patient (ex vivo) to fight against the cancer. In this regard, one of the most exciting approaches involves the use of DC-based vaccines [14, 19-28].

The truth that our immune system can be exploited for control or even eradication of leukemia blasts has created a strong interest in manipulating therapeutic vaccine strategies to increase effective anti-leukemic immunity in AML patients. The rationale of vaccination against AML comes from the facts that AML cells carry leukemia-associated antigens (LAA) which allows them to be targeted and killed by LAA-specific CTL [20]. DCs are professional antigen presenting cells, capable of inducing anti-leukemic immune responses directed against leukemia-associated antigens. They are programmed to digest and present antigen fragments via major histocompatibility complex (MHC) molecules to T cells. In addition to presenting the antigens, DCs express co-stimulatory molecules to prime naïve CD8<sup>+</sup> T cells into antigen-specific CTLs [29].

Recently, DC vaccination has been developed as a promising immunotherapy for cancers including hematological malignancies. Using DCs in clinical trials for therapeutic purposes in cancer patients has been started since the mid-1990s [30]. These antigen presenting cells have the professional ability in orchestrating the immune system and triggering the appropriate immune responses. Culture of DCs ex vivo circumvents the immunosuppressive features of the tumor microenvironments and can lead to eradication of MRD which are a small reservoir of leukemic cells (mostly cancer stem cells) that are resistant to chemotherapy and may evolve to a full clinical relapse [14, 21, 28, 31].

Regarding the limiting use of HSCT to younger patients and no donor available in some patients, scientists are looking for effective and less toxic post-remission therapies to prevent the relapses and to prolong the survival rates. The feasibility of using DCs has been established in many cancers while both

immunological and clinical responses have been reported in several clinical trials in cancer immunotherapy. Therefore, DCs are considered as attractive and potential candidates for anti-tumor or anti-leukemic vaccination strategies [32]. These unique characteristics of DCs have made them exciting tools for generating vaccines that can activate the tumor-specific immune responses.

#### **Possibility of generating blast-derived DCs**

The main sources of DCs for clinical trials are: CD34<sup>+</sup> blood, umbilical cord blood or bone-marrow-derived ancestors, blood DCs, monocytes as well as leukemic blast precursors [33-36]. A major advance arose with the description of a simple method to generate large numbers of blood-derived DC from monocytes by culture in the presence of granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-4 (IL-4). This allocated the design of immunotherapeutic strategies using ex vivo-generated DC as an adjuvant. Monocyte-derived DCs are widely used in clinical trials, in shape of immature DCs (only cultured in IL-4 and GM-CSF) or mature DCs (matured by different factors like cytokine cocktail: IL-1 $\beta$ , IL-6, tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and Prostaglandin E2 (PGE2), often referred to as the "gold standard DCs"). Several pilot clinical trials indicate that mature DCs are superior to immature DCs, at least because of their T-cell stimulatory ability in contrast to regulatory T cell induction of immature DCs [37].

In order to trigger a tumor-specific T cell response in leukemic patients, it is common to pulse monocyte-derived DCs with tumor (or leukemic) antigens which imposes an additional manipulation to the DC generation process [24]. Since it is hard to isolate leukemia-specific antigens from different AML patients, immunogenic DCs can be successfully generated from blasts without needing antigen pulsing [34]. Furthermore, differentiation of blasts into leukemic DCs can elevate their immunogenicity, as demonstrated by the induction of anti-leukemic T cell responses. This clarifies the rationale for attempting to change the leukemic cells into efficient antigen-presenting cells [26]. The first report on successful generating of AML-DCs in vitro by Santiago-Schwartz and *et al.*, opened a promising way toward a simple DC generation method from available blasts for future DC immunotherapy in AML patients [35, 38]. AML-DCs can differentiate from blasts in relapse phase and induce anti-leukemic T-cell responses [39, 40]. These cells can be successfully generated and regain the stimulatory capacity of mature monocyte-derived DCs (i.e. conventional DCs). Bagheri and his colleagues showed that blast-derived DCs can be sufficiently generated in all AML cases and the leukemic origin of them can be confirmed using the expression pattern of angiotensin-converting enzyme (CD143) which its expression is much higher on mo-DCs than AML-DCs [41]. Moreover, Kufner and his colleagues indicated the possibility of generating DCs in AML and MDS patients under serum-free condition, although not all blasts in culture could convert into DC. Besides, they recommended selecting leukemic-DCs for vaccinations or ex vivo T-cell activations to avoid contaminations with non-converted blasts and non-leukemia-derived DC and to improve the yield of specific, anti-leukemic T cells, as well [42]. Research efforts have now focused on optimizing in vitro culture conditions for generating antigen specific leukemic-DCs and their maturation protocols in order to maximize their potential to induce anti-leukemic immunity [19].

According to our previous studies on generating blast-derived DCs, we showed that blasts of more than 70 % of AML

patients mostly with M4 or M5 phenotypes (French-American-British (FAB) classification) could differentiate to DCs (AML-DC) in a 5% AB serum culture condition. Those converted blasts displayed typical DC markers (e.g. CD40, CD86, CD1a, CD83 and CCR7) and revealed the other functional capacities of antigen presenting cells. We also tried to find the most efficient maturation cocktails among different combinations of TLR ligands as recently introduced potent adjuvants [43, 44].

#### **Synergistic effect of TLR-agonists on DC maturation**

Recent studies have focused on attempts to provide appropriate guidelines in order to generate optimally matured DCs with the ability of migration toward lymph nodes and response to licensing stimuli, following administration to a patient with cancer [14]. However, there are controversial reports on DC generation and maturation protocols. For instance, Sporri and his colleagues believed that inflammatory mediators in cytokine cocktail are insufficient for generating fully activated DCs and promote expansion of CD4<sup>+</sup> T cell populations lacking a helper function due to negative regulation properties of PGE2 [45]. Therefore, applying the cytokine cocktail is not the only method used for maturation of human DCs. Kalinski and colleagues have introduced a “megacytokine cocktail” consisting of 5 reagents (TNF- $\alpha$ , IL-1 $\beta$ , Poly (I:C), IFN- $\alpha$ , and IFN- $\gamma$ ), conferring superior immunogenicity and more potent CTL responses [46]. As a result, cocktails containing synthetic TLR agonists such as Poly (I:C) (TLR3 agonist) or R848 (TLR7/8 agonists) came out as attractive alternatives for the induction of DC maturation and subsequent Th1 immune responses via high production of IL-12(p70) [47, 48].

The co-stimulatory features of DCs can be launched by triggering of pathogen recognition receptors (PRRs) such as Toll-like receptors (TLRs), which have a critical role in sensing microbial or viral structures called pathogen-associated molecular patterns (PAMPs) [49, 50]. Expression of at least 11 TLRs on normal or transformed cells of the human immune system has been well established [50, 51]. A variety of TLRs are also expressed by human AML-DCs [52]. Recent studies suggest that adjuvants, including TLR ligands are powerful stimulator for DC maturation by targeting distinct TLRs and their intracellular adaptors. After binding, DCs can directly mediate the innate immune responses by regulating the phagocytic function or differentiate to mature DCs and instruct the adaptive immune responses by secreting the effective cytokines [53, 54]. There are controversial reports on activation of different T cell subsets following TLR binding [55]. Overall, it appears that some ligands (e.g. TLR-3, -4, -5 and -7/8) can shift the immune response toward polarized Th1 responses and/or CTL induction while the others like TLR-2 ligands emerge a Th2 bias [56]. Thus, it can be possible to find appropriate combinations of TLR ligands with the most synergistic effect on DC maturation and function to stimulate a potent antitumor immune response. In addition to eliciting a desired immune response, it may also be accompanied with the strategies to overcome the immunosuppressive microenvironment in the tumor periphery [57].

Combination of poly(I:C) binding as an TRIF activator via an MyD88-independent pathway, along with the bindings of TLR4 and TLR7/8 for MyD88-dependent pathway have been investigated on AML-DCs in our published study. Phenotypic evaluation of AML-DCs stimulated with LPS alone or in combination with R848 and/or poly(I:C) revealed, to some extent, a similar expression pattern of DC markers and costimulatory molecules expressed on conventional monocyte-

derived DCs. We found that a combination of LPS + R848 and LPS + R848 + poly(I:C) provide the highest percentages of DCs expressing HLA-DR and CD86. High expression of these two molecules was accompanied with a strong allostimulatory capacity of the relevant AML-DCs in allo-MLR [43].

Similarly, Bohnenkamp *et al.* indicated that potent and efficient T-helper cell type 1 response can be elicited by monocyte-derived DCs after TLR engagement with poly(I:C) or LPS and R848 [58]. High levels of IL-12 (p70) production by monocyte-derived DCs prepared in the presence of TLR3 and TLR7/8 agonists have been reported in other studies [59, 60]. Although LPS by itself can induce recruitment of both MyD88/TIRAP and TRIF/TRAM adaptor proteins, our results showed that LPS alone is not sufficient to generate potent AML-DCs and needs to be accompanied with a synergized signal. In parallel, Roses *et al.* reported that multiple signals of agonists are required for commitment of the antigen presenting cells toward Th1 immune responses [65].

#### **In vitro evaluation of generated DCs**

There are different protocols for assessing the antigen presenting and T cell activating ability of in vitro-generated DCs. As minimum requirements for DC evaluation, it is common to assess the features described in Fig. 1.

Specific DC surface markers (immunophenotyping) change during the differentiation of DCs from the precursors (monocytes, bone marrow precursors, blasts, etc.). As a results of our and previous studies on AML-DCs, CD14<sup>+</sup> and CD86<sup>+</sup>, blasts are more susceptible to be differentiated to AML-DCs [43, 61-63]. Contrary to CD14 which decreases during the differentiation of blast into immature and mature DCs, the expression pattern and especially mean florescent intensity (MFI) of CD86 increase gradually until full maturity of DCs. Elevating expression of CD11c, CD40, HLA-DR and CD83 (human DC maturation marker) following DC generation and subsequent maturation procedure can be found in AML-DC in parallel to the cognate monocyte-derived DCs. We also found that higher expression of CD1a occurs in the presence of 10% FBS instead of 5% AB serum-conditioned culture medium [43, 64].

#### **Key cytokines which shift the immune response toward Th1, Th2, Th17 or Treg cells.**

DCs produce different cytokines like IL-12, IL-10, IL-23, IL-6 and IL-1 $\beta$ , especially after stimulating with TLR agonists [65]. Attachment of cytokines to their matching receptors on T cells, triggers the internal signals in the direction of T cell activation corresponding to the required function for eliminating the pathogens or tumor cells [50, 66]. In cancer immunotherapy approaches, it is important to generate DCs with a sustained ability for producing Th1-shifting cytokines, especially IL-12. In our study, the production of IL-12(p70) was superior by AML-DCs matured using TLR4 and TLR7/8 agonists with or without adding TLR3 agonist (i.e. the best combinations) [44]. There are different methods with various sensitivities for intracellular (non-secreted) or secreted cytokine assessment including flow cytometry, ELISPOT/ELISA methods, respectively.

Allostimulatory function can be measured through the stimulatory capacity of irradiated DCs in a primary MLR assay (co-culture setting) with allogeneic T cells. Potent DCs especially those activated by TLR agonists can elicit a strong proliferation activity among T cells according to the allogenic differences between MHC on DCs and TCR on T cells [67]. There are different methods with various sensitivity for T cell proliferation assessment including MTT, XTT, Brdu labeling

protocol (ELISA, Chemiluminescence or flow cytometry), live cell labeling (CFSE, orange dye, etc.). In addition, cytokine production of T cells (like IFN- $\gamma$ , IL-4, IL-10, IL-17, etc.) is being assessed to find out the preferred T cell subsets in the co-culture system. Gamma interferon is a key cytokine of Th1-shifted T cells which are important in anti-leukemic responses. As a result of our study, AML-DCs matured with TLR4 plus TLR7/8 agonists with or without TLR3 agonist can stimulate allogeneic T cell responses more potently than the other conditioned cells [44].

#### **CTLs induction and target-specific killing activity of CTLs.**

In cancer immunotherapy, it is very important to stimulate effector and specific CTLs for targeting malignant cells. CTL induction performs to mimic the *in vivo* capability of DCs for stimulating CTLs and the subsequent killing of the target cells [68]. For achieving such induction, autologous T cells should be taken in remission phase and be co-cultured with tumor specific DCs for 21 days (this may vary between different protocols). The cells also need to be re-stimulated by DCs and be replenished with IL-2/IL-7, every 3 days. After harvesting the CTLs, they are ready for killing the targets (tumor cells, blasts, etc.) [44]. Cytotoxicity can be measured by different methods. Some of them are chromium release assay, target cell labeling (CFSE, orange, etc.) and also detecting CD107a by flow cytometry for the effector cells.

#### **Phagocytic function**

Immature DCs have the highest capacity of phagocytosis which gradually decreases after maturation and starting of their migration. This phenomenon helps DCs to internalize foreign particles, process and subsequently present them in the presence of major histocompatibility molecules (MHCs) to naïve T cells. There are different methods to detect the phagocytic function of DCs. Most of them are based on the ingestion of fluorochrome-conjugated particles including carbohydrates (dextran) or bacteria (*E. coli* or *S. aureus*), detectable by flow cytometry. After releasing the statistical analyses of flow cytometric data, the proportion of phagocytic cells and the number of the ingested particles can easily be determined according to the percentage of gated cells and related mean fluorescent intensity (MFI), respectively.

#### **Outcomes of DC vaccine trials in AML and lessons that could be learned**

Cancer immunotherapy has recently been named in Science as “breakthrough of the year”; therefore, we have in our hand a promising strategy and potential weapon to harness the cancer patients’ immune responses [69]. There are several clinical trials on AML patients containing DC-based vaccines which were registered in <www.ClinicalTrials.gov>. By a quick search in the website with the keywords: “dendritic cell vaccination in cancer/tumor”, we could find 302 registered clinical trials. Of those, 13 clinical trials belonged to DC vaccination with or without conventional therapies for AML patients. Obviously, DCs should be produced in a good clinical practice (GCP) setting in order to be used in clinical trials (Fig. 1). For AML-DC vaccination, it is necessary to irradiate the cells prior to the administration for preventing the uncontrolled proliferation of probably undifferentiated blasts in the vaccine [70]. According to the results, there are controversial outcomes in immunological and clinical responses of DC-based vaccination in AML patients.

Apparently, it would be more effective to use the cancer vaccines in patients with minimal disease burden after conventional therapies rather than in newly diagnosed or non-

treated relapsed patients with a compromised immune system [71]. Although there are several clinical trials using leukemic DCs [70, 72], a more thorough investigation is needed to establish a technical procedure for producing AML-DCs with a potent immunostimulatory activity in all subtypes of AML patients [11]. The preference of using monocyte-derived DCs, especially in AML patients with minimal residual disease, has been shown in recent studies,; although the first report was not successful in AML patients with high tumor burden [73]. In contrast, Van Tendeloo *et al.* observed complete remission in 8 patients with elevated WT1 mRNA level and 2 patients in partial remission (PR) following injections of full-length WT1 mRNA-electroporated DCs as a post-remission treatment. High numbers of WT1-specific CD8+ T cells were also in line with clinical responses [74]. Kitawaki *et al.* recently published two clinical studies on mo-DC vaccination subsequent to morphologic remission in elderly AML patients. In the first trial, they could induce immune response with stable condition in 2 of 4 patients following administration of TLR4 agonist activated mo-DCs, enabling to cross-present endocytosed autologous apoptotic leukemia cell antigens [75]. In the other report, although mo-DCs were pulsed with zoledronate and an HLA-A\*24:02-restricted modified WT1 peptide (with higher affinity to HLA than natural WT1 peptide), the transient period of stabilization was observed in 2 of 3 evaluated patients, despite expansion of anti-WT1 CD8+ T cell response. More persistent CD8 T cells, specific for natural WT1 than modified peptide, indicated the preference of using the former molecule in DC-based vaccines [76].

In a recent review study on Wilms’ tumor protein 1 (WT1)-targeted active specific immunotherapy, Driessche *et al.* showed objective clinical responses (including stable disease) in 46% and 64% and specific immunological responses in 35% and 68% of solid tumors and hematological malignancies, respectively. Due to achieving the first rank by WT1 (as a result of National Cancer Institute Prioritization Project) as well as considerable clinical results and minimal side effects, WT1-cancer vaccines have been shown to be a promising immunotherapy as a standard vaccination in patients with various tumor types [77]. Moreover, the possibility of producing fusion DCs and AML blast and the *in vivo* activity of fusion cells have been shown in a phase I clinical trial. The authors could find the expansion of bone marrow infiltrating AML reactive T cells in the patients [78]. In another study, a 23-month remaining in remission was reported in 9 of 13 evaluable AML patients who had received vaccination with DC/leukemia fusion cells after remission [79]. Hopeful investigations are ongoing to use the TLR-DCs in combination with the other modalities like blocking of checkpoint molecules (e.g. CTLA4) or dampening the immunosuppressive factors [78].

There are different results on overall survival rates of AML patients in various clinical trials; however, the best results are related to studies which have considered all important aspects of designing a vaccination protocol. These factors include the process of generating mature leukemic or monocyte derived antigen specific-DCs, overcoming the immunosuppressive milieu, timing of injection, route and dose of vaccination, overall tumor burden as well as knowing the characteristics of LSCs to target them [78]. Although the exact immunophenotype of the LSCs is still unclear, CD123 (IL-3R) is constitutively expressed on both LSCs and leukemic cells and is a promising therapeutic target for AML. Leukemic antigen specific-DCs can indeed provoke the immune

responses in AML patients, nonetheless other modalities are required to potentiate the MRD-eradicating capacity of AML-DCs, such as steering the tolerized immunity toward immunized immunity [25]. More notably, few recent DC vaccinations studies after allo-HCT have shown to be safe and efficient regarding both clinical and immunological responses. Hopefully, the field is open for further investigations, especially with the current approaches in achievable combination therapies to lessen the relapse rates and improve the survival rates [80]. To wrap up, these reports point to the feasibility of using DC-based immunotherapy as an immunogenic adjuvant after remission-induction therapy in AML patients, although it necessitates further studies.


### The importance of combination strategies in future therapeutic approaches

Although DCs are key orchestrators of the immune system to communicate with cells of both adaptive and innate immunity, a vaccine strategy for AML is presumably to be effective if it targets different anti-leukemic immune pathways. In this regard, DC vaccines can be designed to activate the key cells of innate immunity like NK cells or to be combined with the other immunotherapeutic approaches. Regarding the tumor control role of NK cells and their multiple defects in AML patients [81, 82], future research efforts should also concentrate on optimizing the NK cell activating properties of DC vaccines, in addition to improving their T cell stimulatory capacity.

In this point of view, it will be very interesting to investigate the IL-15-treated DCs for their capacity to activate NK cells or particularly restore the impaired NK cell functions of AML patients [19]. By the way, due to the immunosuppressive microenvironment in AML, it appears that DC vaccination by itself may not be sufficient to induce protective anti-leukemic immunity. Thus, it needs to reverse the immune suppression,

using therapeutic agents in combination with DC-based vaccines.

One approach would be blocking the immune suppression-mediated molecules, like the PD/PDL interaction, CTLA-4, CD200, reactive oxygen species, IDO expression, CXCR4, or the KIR/class I interaction [83]. In a recent study conducted by Memarian *et al*, a considerable association between the expansion of Foxp3+ regulatory T cells and CD200 up regulation on blasts of Iranian AML patients was shown. Accordingly, the blockade of CD200-CD200R interaction could be a promising target for AML immunotherapy [84]. Indeed, DC vaccination plus CTLA-4 blockade (as a checkpoint molecule) was shown to be superior to vaccination alone in terms of eliciting an AML-specific T cell response in vitro [85]. While at first it seems to be an attractive strategy, it might have unfavorable effects than beneficial ones in vivo since CTLA-4 blockade can induce an undesired proliferation of regulatory T cells (Treg) [86]. Conceivably, a more clinically workable tactic for combination therapy is to apply Treg depletion before DC vaccination in order to avoid non-selective elimination of vaccine-induced T cells. Antibody-mediated removal of CD25+ Treg in a mouse model of AML significantly enhanced the efficacy of subsequent DC vaccination [87]. Apart from improving the immunostimulatory activity of DC vaccines, we should think about the immunoeediting ability of blasts to protect them against the immune attacks which can weaken the vaccine efficacy [88]. There are different strategies to increase the immunogenicity of AML cells together with DC vaccination, such as cytokines like IFN- $\alpha$  or Toll-like receptor ligands like resiquimod (R848) as TLR7/8 ligand [89, 90]. Obviously, there are more possible combinations of anticancer agents than described here that can result to a considerable improvement in DC vaccine efficacy.



**Fig. 1.** A scheme of DC-based tumor vaccine preparation. DCs can be generated from peripheral blood or bone marrow blasts by culture in the presence of GMCSF and IL-4. AML-DCs do not usually need to be loaded with leukemic antigens and just need to be stimulated with maturation signals like cytokines and/or TLR agonists. Then, clinical grade DCs can be administered to the patient. There are many parameters that should be considered containing the source of DCs, maturation agents, and the route of administration.

High incidence of relapse following chemotherapy in majority of AML patients is a powerful incentive for scientist to find alternative therapeutic approaches to improve the patients' endurance. Low rate of long-term survival can be largely attributed to the presence of minimal residual diseases (MRDs) despite intensive chemotherapy. Thus, it is indispensable to find effective interventions to control MRDs and prevent relapses. DCs can be generated from blasts of AML patients (especially in M4 and M5 patients) and be used as a post-remission therapy. To potentiate the vaccine efficacy, it may be combined with anticancer or immunomodulatory agents. More noticeably, in order to uncover the full potential capacity of DC vaccines, future studies comprising both experimental models and clinical trials will be needed.

## AUTHOR'S CONTRIBUTION

Maryam Nourizadeh has written and Jamshid Hadjati has revised and edited the manuscript.

## ACKNOWLEDGEMENTS

We would like to thank all scientists who are working hard to find the ways for curing the cancer patients and all patients who attend the research studies.

## CONFLICTING INTERESTS

We have no conflicts of interest to declare.

## REFERENCES

1. Farnault L, Sanchez C, Baier C, Le Treut T, Costello RT. Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications. *Clinical & developmental immunology*. 2012;2012:421702. doi:10.1155/2012/421702.
2. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. *Blood*. 2009;114(5):937-51. doi:10.1182/blood-2009-03-209262.
3. Estey E, Dohner H. Acute myeloid leukaemia. *Lancet*. 2006;368(9550):1894-907. doi:10.1016/S0140-6736(06)69780-8.
4. Lin TL, Levy MY. Acute myeloid leukemia: focus on novel therapeutic strategies. *Clinical Medicine Insights Oncology*. 2012;6:205-17. doi:10.4137/CMO.S7244.
5. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. *The New England journal of medicine*. 1999;341(14):1051-62. doi:10.1056/NEJM199909303411407.
6. Yoon SK. The biology of cancer stem cells and its clinical implication in hepatocellular carcinoma. *Gut and liver*. 2012;6(1):29-40. doi:10.5009/gnl.2012.6.1.29.
7. Jordan CT, Guzman ML. Mechanisms controlling pathogenesis and survival of leukemic stem cells. *Oncogene*. 2004;23(43):7178-87. doi:10.1038/sj.onc.1207935.
8. Schurch CM, Riether C, Ochsenein AF. Dendritic cell-based immunotherapy for myeloid leukemias. *Frontiers in immunology*. 2013;4:496. doi:10.3389/fimmu.2013.00496.
9. Lowenberg B, Griffin JD, Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia. *Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program*. 2003:82-101.
10. Smith M, Barnett M, Bassan R, Gatta G, Tondini C, Kern W. Adult acute myeloid leukaemia. *Critical reviews in oncology/hematology*. 2004;50(3):197-222. doi:10.1016/j.critrevonc.2003.11.002.
11. Draube A, Beyer M, Wolf J. Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived

- dendritic cells. *European journal of haematology*. 2008;81(4):281-8. doi:10.1111/j.1600-0609.2008.01110.x.
12. Smits EL, Lee C, Hardwick N, Brooks S, Van Tendeloo VF, Orchard K et al. Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia. *Cancer immunology, immunotherapy : CII*. 2011;60(6):757-69. doi:10.1007/s00262-011-1022-6.
13. Galea-Lauri J. Immunological weapons against acute myeloid leukaemia. *Immunology*. 2002;107(1):20-7.
14. Gilboa E. DC-based cancer vaccines. *The Journal of clinical investigation*. 2007;117(5):1195-203. doi:10.1172/JCI31205.
15. Greiner J, Dohner H, Schmitt M. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens. *Haematologica*. 2006;91(12):1653-61.
16. Caligiuri MA, Velardi A, Scheinberg DA, Borrello IM. Immunotherapeutic approaches for hematologic malignancies. *Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program*. 2004:337-53. doi:10.1182/asheducation-2004.1.337.
17. Perez SA, Papamichail M. Cancer immunotherapy: perspectives and prospects. *Advances in experimental medicine and biology*. 2008;622:235-53. doi:10.1007/978-0-387-68969-2\_19.
18. Borrello IM, Sotomayor EM. Cancer vaccines for hematologic malignancies. *Cancer control : journal of the Moffitt Cancer Center*. 2002;9(2):138-51.
19. Anguille S, Lion E, Smits E, Berneman ZN, van Tendeloo VF. Dendritic cell vaccine therapy for acute myeloid leukemia: questions and answers. *Human vaccines*. 2011;7(5):579-84.
20. Anguille S, Willems Y, Lion E, Smits EL, Berneman ZN. Dendritic cell vaccination in acute myeloid leukemia. *Cytotherapy*. 2012;14(6):647-56. doi:10.3109/14653249.2012.693744.
21. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. *Nat Rev Immunol*. 2005;5(4):296-306.
22. Brugger S, Schneider A, Schammann T, Dill P, Grunebach F, Buhning HJ et al. Dendritic cell-based vaccines in patients with hematological malignancies. *Annals of the New York Academy of Sciences*. 2001;938:359-62; discussion 62-3.
23. Buchler T, Michalek J, Kovarova L, Musilova R, Hajek R. Dendritic cell-based immunotherapy for the treatment of hematological malignancies. *Hematology*. 2003;8(2):97-104. doi:10.1080/1024533031000084204.
24. Delluc S, Tourneur L, Fradelizi D, Rubio MT, Marchiol-Fournigault C, Chiochia G et al. DC-based vaccine loaded with acid-eluted peptides in acute myeloid leukemia: the importance of choosing the best elution method. *Cancer immunology, immunotherapy : CII*. 2007;56(1):1-12. doi:10.1007/s00262-006-0170-6.
25. Houtenbos I, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA. Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia. *Haematologica*. 2006;91(3):348-55.
26. Houtenbos I, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA. Leukaemic dendritic cell vaccination for patients with acute myeloid leukaemia. *British journal of haematology*. 2006;134(4):445-6; author reply 6-7. doi:10.1111/j.1365-2141.2006.06196.x.
27. Kufner S, Zitzelsberger H, Kroell T, Pelka-Fleischer R, Salem A, de Valle F et al. Leukaemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with myelodysplasia: a methodological approach under serum-free culture conditions. *Scandinavian journal of immunology*. 2005;62(1):75-85. doi:10.1111/j.1365-3083.2005.01631.x.
28. Schmitt A, Hus I, Schmitt M. Dendritic cell vaccines for leukemia patients. *Expert review of anticancer therapy*. 2007;7(3):275-83. doi:10.1586/14737140.7.3.275.
29. Barrett AJ, Le Blanc K. Immunotherapy prospects for acute myeloid leukaemia. *Clinical and experimental immunology*. 2010;161(2):223-32. doi:10.1111/j.1365-2249.2010.04197.x.
30. Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. *Lancet Oncol*. 2014;15(7):e257-67.
31. van den Ancker W, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA. Back to basics: in search of the optimal dendritic cell for vaccination in AML. *Leukemia research*. 2008;32(11):1641-3. doi:10.1016/j.leukres.2008.03.029.
32. Ridgway D. The first 1000 dendritic cell vaccinees. *Cancer investigation*. 2003;21(6):873-86.
33. Grabrucker C, Liepert A, Dreyig J, Kremser A, Kroell T, Freudenreich M et al. The quality and quantity of leukemia-derived dendritic cells from

patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells. *Journal of immunotherapy*. 2010;33(5):523-37. doi:10.1097/CJI.0b013e3181d87ffd.

34. Kremser A, Dressig J, Grabrucker C, Liepert A, Kroell T, Scholl N et al. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods. *Journal of immunotherapy*. 2010;33(2):185-99. doi:10.1097/CJI.0b013e3181b8f4ce.

35. Santiago-Schwarz F, Coppock DL, Hindenburg AA, Kern J. Identification of a malignant counterpart of the monocyte-dendritic cell progenitor in an acute myeloid leukemia. *Blood*. 1994;84(9):3054-62.

36. Eisendle K, Wolf D, Gastl G, Kircher-Eibl B. Dendritic cells from patients with chronic myeloid leukemia: functional and phenotypic features. *Leukemia & lymphoma*. 2005;46(5):663-70. doi:10.1080/10428190400029825.

37. Nestle FO, Farkas A, Conrad C. Dendritic-cell-based therapeutic vaccination against cancer. *Current opinion in immunology*. 2005;17(2):163-9. doi:10.1016/j.coi.2005.02.003.

38. Cignetti A, Vallario A, Roato I, Circosta P, Allione B, Casorzo L et al. Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses. *Journal of immunology*. 2004;173(4):2855-65.

39. Kufner S, Zitzelsberger H, Kroell T, Pelka-Fleischer R, Salem A, de Valle F et al. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions. *Scand J Immunol*. 2005;62(1):86-98.

40. Houtenbos I, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA. Employing the immunological synapse in AML: development of leukemic dendritic cells for active specific immunization. *Immunobiology*. 2005;210(2-4):249-57. doi:10.1016/j.imbio.2005.05.019.

41. Bagheri K, Alimoghaddam K, Pourfathollah AA, Hassan ZM, Hajati J, Moazzeni SM. The efficient generation of immunocompetent dendritic cells from leukemic blasts in acute myeloid leukemia: a local experience. *Pathology oncology research : POR*. 2009;15(2):257-67. doi:10.1007/s12253-008-9105-1.

42. Kufner S, Fleischer RP, Kroell T, Schmid C, Zitzelsberger H, Salih H et al. Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes. *Cancer immunology, immunotherapy : CII*. 2005;54(10):953-70. doi:10.1007/s00262-004-0657-y.

43. Nourizadeh M, Masoumi F, Memarian A, Alimoghaddam K, Moazzeni SM, Hadjati J. Synergistic effect of Toll-like receptor 4 and 7/8 agonists is necessary to generate potent blast-derived dendritic cells in Acute Myeloid Leukemia. *Leukemia research*. 2012;36(9):1193-9. doi:10.1016/j.leukres.2012.04.007.

44. Nourizadeh M, Masoumi F, Memarian A, Alimoghaddam K, Moazzeni SM, Yaghmaie M et al. In vitro induction of potent tumor-specific cytotoxic T lymphocytes using TLR agonist-activated AML-DC. *Targeted oncology*. 2014;9(3):225-37. doi:10.1007/s11523-013-0285-6.

45. Sporri R, Reis e Sousa C. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. *Nat Immunol*. 2005;6(2):163-70.

46. Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML et al. alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. *Cancer research*. 2004;64(17):5934-7. doi:10.1158/0008-5472.CAN-04-1261.

47. Beck B, Dorfel D, Lichtenegger FS, Geiger C, Lindner L, Merk M et al. Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission. *Journal of translational medicine*. 2011;9:151. doi:10.1186/1479-5876-9-151.

48. Nourizadeh M, Masoumi F, Memarian A, Alimoghaddam K, Moazzeni SM, Hadjati J. Synergistic effect of Toll-like receptor 4 and 7/8 agonists is necessary to generate potent blast-derived dendritic cells in Acute Myeloid Leukemia. *Leukemia research*. 2012;36(9):1193-9. doi:10.1016/j.leukres.2012.04.007.

49. Kawai T, Akira S. TLR signaling. *Seminars in immunology*. 2007;19(1):24-32. doi:10.1016/j.smim.2006.12.004.

50. Schreibelt G, Tel J, Slieden KH, Benitez-Ribas D, Figdor CG, Adema GJ et al. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. *Cancer immunology, immunotherapy : CII*. 2010;59(10):1573-82. doi:10.1007/s00262-010-0833-1.

51. Wolska A, Lech-Maranda E, Robak T. Toll-like receptors and their role in hematologic malignancies. *Current molecular medicine*. 2009;9(3):324-35.

52. Schmitt A, Li L, Giannopoulos K, Greiner J, Reinhardt P, Wiesneth M et al. Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia. *Transfusion*. 2008;48(5):861-70. doi:10.1111/j.1537-2995.2007.01616.x.

53. Krutzik SR, Tan B, Li H, Ochoa MT, Liu PT, Sharfstein SE et al. TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. *Nature medicine*. 2005;11(6):653-60. doi:10.1038/nm1246.

54. Killeen SD, Wang JH, Andrews EJ, Redmond HP. Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword? *British journal of cancer*. 2006;95(3):247-52. doi:10.1038/sj.bjc.6603275.

55. Conroy H, Marshall NA, Mills KH. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. *Oncogene*. 2008;27(2):168-80. doi:10.1038/sj.onc.1210910.

56. Agrawal S, Agrawal A, Doughty B, Gerwitz A, Blenis J, Van Dyke T et al. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. *Journal of immunology*. 2003;171(10):4984-9.

57. Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T et al. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. *Science*. 2005;309(5739):1380-4. doi:10.1126/science.1113401.

58. Bohnenkamp HR, Papazisis KT, Burchell JM, Taylor-Papadimitriou J. Synergism of Toll-like receptor-induced interleukin-12p70 secretion by monocyte-derived dendritic cells is mediated through p38 MAPK and lowers the threshold of T-helper cell type 1 responses. *Cellular immunology*. 2007;247(2):72-84. doi:10.1016/j.cellimm.2007.07.008.

59. Spranger S, Javorovic M, Burdek M, Wilde S, Mosetter B, Tippmer S et al. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. *Journal of immunology*. 2010;185(1):738-47. doi:10.4049/jimmunol.1000060.

60. Zobywalski A, Javorovic M, Frankenberger B, Pohla H, Kremmer E, Bigalke I et al. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. *Journal of translational medicine*. 2007;5:18. doi:10.1186/1479-5876-5-18.

61. Houtenbos I, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA. Identification of CD14 as a predictor for leukemic dendritic cell differentiation in acute myeloid leukemia. *Leukemia*. 2003;17(8):1683-4; author reply 4; discussion 5. doi:10.1038/sj.leu.2403014.

62. Mohty M, Gaugler B, Olive D. Generation of leukemic dendritic cells from patients with acute myeloid leukemia. *Methods in molecular biology*. 2003;215:463-71.

63. Re F, Arpinati M, Testoni N, Ricci P, Terragna C, Preda P et al. Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage. *Experimental hematology*. 2002;30(2):126-34.

64. Gogolak P, Rethi B, Szatmari I, Lanyi A, Dezso B, Nagy L et al. Differentiation of CD1a- and CD1a+ monocyte-derived dendritic cells is biased by lipid environment and PPARgamma. *Blood*. 2007;109(2):643-52. doi:10.1182/blood-2006-04-016840.

65. Roses RE, Xu S, Xu M, Koldovsky U, Koski G, Czerniecki BJ. Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists. *Journal of immunology*. 2008;181(7):5120-7.

66. Sioud M, Floisand Y. TLR agonists induce the differentiation of human bone marrow CD34+ progenitors into CD11c+ CD80/86+ DC capable of inducing a Th1-type response. *European journal of immunology*. 2007;37(10):2834-46. doi:10.1002/eji.200737112.

67. Tourkova IL, Yurkovetsky ZR, Shurin MR, Shurin GV. Mechanisms of dendritic cell-induced T cell proliferation in the primary MLR assay. *Immunology letters*. 2001;78(2):75-82.

68. Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. *Cancer immunology, immunotherapy : CII*. 2002;51(6):299-310. doi:10.1007/s00262-002-0284-4.

69. McNutt M. Cancer immunotherapy. *Science*. 2013;342(6165):1417. doi:10.1126/science.1249481.

70. Roddie H, Klammer M, Thomas C, Thomson R, Atkinson A, Sproul A et al. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. *British journal of haematology*. 2006;133(2):152-7. doi:10.1111/j.1365-2141.2006.05997.x.

71. Kitawaki T. DC-based immunotherapy for hematological malignancies. *International journal of hematology*. 2014;99(2):117-22. doi:10.1007/s12185-013-1496-4.
72. Li L, Giannopoulos K, Reinhardt P, Tabarkiewicz J, Schmitt A, Greiner J et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. *International journal of oncology*. 2006;28(4):855-61.
73. Lee JJ, Kook H, Park MS, Nam JH, Choi BH, Song WH et al. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. *Journal of clinical apheresis*. 2004;19(2):66-70. doi:10.1002/jca.10080.
74. Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. *Proceedings of the National Academy of Sciences of the United States of America*. 2010;107(31):13824-9. doi:10.1073/pnas.1008051107.
75. Kitawaki T, Kadowaki N, Fukunaga K, Kasai Y, Maekawa T, Ohmori K et al. Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia. *Experimental hematology*. 2011;39(4):424-33 e2. doi:10.1016/j.exphem.2011.01.001.
76. Kitawaki T, Kadowaki N, Fukunaga K, Kasai Y, Maekawa T, Ohmori K et al. A phase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co-pulsed with WT1 peptide and zoledronate. *British journal of haematology*. 2011;153(6):796-9. doi:10.1111/j.1365-2141.2010.08490.x.
77. Van Driessche A, Berneman ZN, Van Tendeloo VF. Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. *The oncologist*. 2012;17(2):250-9. doi:10.1634/theoncologist.2011-0240.
78. Larkin K, Blum W. Novel therapies in AML: reason for hope or just hype? *American Society of Clinical Oncology educational book / ASCO American Society of Clinical Oncology Meeting*. 2014:e341-51. doi:10.14694/EdBook\_AM.2014.34.e341.
79. Rosenblatt JR SR, Uhl L, Donna S, Neuberger S, Baldev Vasir P, 2., Poorvi Somaiya\*, Robin Joyce M et al. Clinical trial evaluating DC/AML fusion cell vaccination in AML patients. *Blood*. 2013;122:3928.
80. Plantinga M, de Haar C, Nierkens S, Boelens JJ. Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control? *Frontiers in immunology*. 2014;5:218. doi:10.3389/fimmu.2014.00218.
81. Fauriat C, Moretta A, Olive D, Costello RT. Defective killing of dendritic cells by autologous natural killer cells from acute myeloid leukemia patients. *Blood*. 2005;106(6):2186-8. doi:10.1182/blood-2005-03-1270.
82. Khaznadar Z, Henry G, Setterblad N, Agaoglu S, Raffoux E, Boissel N et al. Acute myeloid leukemia impairs natural killer cells through the formation of a deficient cytotoxic immunological synapse. *European journal of immunology*. 2014;44(10):3068-80. doi:10.1002/eji.201444500.
83. Martner A, Thoren FB, Aurelius J, Hellstrand K. Immunotherapeutic strategies for relapse control in acute myeloid leukemia. *Blood reviews*. 2013;27(5):209-16. doi:10.1016/j.blre.2013.06.006.
84. Memarian A, Nourizadeh M, Masoumi F, Tabrizi M, Emami AH, Alimoghaddam K et al. Upregulation of CD200 is associated with Foxp3+ regulatory T cell expansion and disease progression in acute myeloid leukemia. *Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine*. 2013;34(1):531-42. doi:10.1007/s13277-012-0578-x.
85. Zhong RK, Loken M, Lane TA, Ball ED. CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system. *Cytotherapy*. 2006;8(1):3-12. doi:10.1080/14653240500499507.
86. Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B et al. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. *Blood*. 2008;112(4):1175-83. doi:10.1182/blood-2007-11-125435.
87. Delluc S, Hachem P, Rusakiewicz S, Gaston A, Marchiol-Fournigault C, Tourneur L et al. Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response. *Cancer immunology, immunotherapy : CII*. 2009;58(10):1669-77. doi:10.1007/s00262-009-0678-7.
88. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoeediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. *Advances in immunology*. 2006;90:1-89. doi:10.1016/S0065-2776(06)90001-7.
89. Schon MP, Schon M. TLR7 and TLR8 as targets in cancer therapy. *Oncogene*. 2008;27(2):190-9. doi:10.1038/sj.onc.1210913.
90. Anguille S, Lion E, Willemsen Y, Van Tendeloo VF, Berneman ZN, Smits EL. Interferon-alpha in acute myeloid leukemia: an old drug revisited. *Leukemia*. 2011;25(5):739-48. doi:10.1038/leu.2010.324.